Zytiga Cleared Fast In Refractory CRPC, Can It Also Move To Earlier Use?
This article was originally published in The Pink Sheet Daily
Executive Summary
J&J's abiraterone is cleared for use two months ahead of schedule. Pricing of $5,000 a month is much lower than Dendreon's Provenge, approved for earlier stage disease.